Are value-based agreements the solution to high drug prices?
Drug prices are high. We should only be paying high prices for drugs that have a major impact on patient health and quality of life. Ergo, we should be paying for drugs with value-based agreements (VBAs), right? It turns out the answer is not so simple. A paper by Dubois, Westrich and Buelt (2020) argue…